Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by University of Washington
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Washington
ClinicalTrials.gov Identifier:
NCT01411098
First received: August 4, 2011
Last updated: March 24, 2014
Last verified: March 2014

August 4, 2011
March 24, 2014
October 2011
June 2014   (final data collection date for primary outcome measure)
Maximum tolerated dose of radiotherapy, in terms of number of daily fractions, that can be delivered using 3D-CRT or IMRT with the standard cisplatin/etoposide regimen [ Time Frame: Up to 8 weeks after completion of radiotherapy ] [ Designated as safety issue: Yes ]
The MTD will be the highest dose at which no more than one of six patients experience a dose-limiting toxicity (DLT). Toxicity will be scored using the National Cancer Institute (NCI) Common Toxicity Criteria version 4.0.
Maximum tolerated dose of radiotherapy, in terms of number of daily fractions, that can be delivered using 3D-CRT or IMRT with the standard cisplatin/etoposide regimen [ Time Frame: Weekly during treatment and then for 8 weeks after completion of radiotherapy ] [ Designated as safety issue: Yes ]
The MTD will be the highest dose at which no more than one of six patients experience a dose-limiting toxicity (DLT). Toxicity will be scored using the National Cancer Institute (NCI) Common Toxicity Criteria version 4.0.
Complete list of historical versions of study NCT01411098 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
A Phase I Dose-intensification Study Using Radiation Therapy and Concurrent Cisplatin and Etoposide for Patients With Inoperable Non-small Cell Lung Cancer

This phase I trial studies the side effects and best dose of radiation therapy when given together with cisplatin and etoposide in treating patients with non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Drugs, such as cisplatin, may make tumor cells more sensitive to radiation therapy. Giving radiation therapy together with cisplatin and etoposide may kill more tumor cells

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of escalating doses of radiotherapy (RT) administered concomitantly with a fixed dose of cisplatin and etoposide within the same overall treatment time.

OUTLINE: This is a dose-escalation study of radiation therapy.

Patients undergo 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) 5 days a week for 8 weeks. Patients also receive cisplatin intravenously (IV) over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5 and 28-32.

After completion of study treatment, patients are followed up at 8 weeks and 6 months.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Recurrent Non-small Cell Lung Cancer
  • Stage IIB Non-small Cell Lung Cancer
  • Stage IIIA Non-small Cell Lung Cancer
  • Stage IIIB Non-small Cell Lung Cancer
  • Radiation: 3-dimensional conformal radiation therapy
    Undergo 3D-CRT
    Other Names:
    • 3D conformal radiation therapy
    • 3D-CRT
  • Radiation: intensity-modulated radiation therapy
    Undergo IMRT
    Other Name: IMRT
  • Drug: cisplatin
    Given IV
    Other Names:
    • CACP
    • CDDP
    • CPDD
    • DDP
  • Drug: etoposide
    Given IV
    Other Names:
    • EPEG
    • VP-16
    • VP-16-213
Experimental: Treatment (radiation therapy and chemotherapy)
Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.
Interventions:
  • Radiation: 3-dimensional conformal radiation therapy
  • Radiation: intensity-modulated radiation therapy
  • Drug: cisplatin
  • Drug: etoposide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
15
Not Provided
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with confirmed unresectable Stage IIB or Stage III non-small cell lung cancer of any histologic-subtype appropriate for definitive concurrent chemotherapy and radiation as determined by multi-disciplinary assessment; all detectable tumor should be encompassable by radiation therapy fields, including both the primary tumor and the involved regional lymph nodes
  • Granulocytes >= 1500/ul
  • Platelets >= 100,000/ul
  • Bilirubin < 1.5 mg/dl
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) < 2 upper limit of normal (ULN)
  • Creatinine clearance must be > 60ml/min
  • Eastern Cooperative Oncology Group (ECOG) 0 to 1
  • Weight loss =< 5% in the previous six months unless weight loss is intentional (per judgment of study medical doctor [MD])
  • Forced expiratory volume in one second (FEV1) must be >= 1.0 L
  • Patients must sign a study-specific informed consent form prior to study entry
  • Patients must have measurable disease on the 3D planning computed tomography (CT)
  • Patient must have a completed 3D plan and the attending physician must have reviewed and approved the dose volume histograms as follows: total lung volume percentage receiving at least 20 Gy (V20) =< 35%, and mean lung dose =< 20 Gy

Exclusion Criteria:

  • Mixed histology or undifferentiated small cell carcinoma, any stage
  • Concurrent malignancy except non-melanomatous skin cancer or prior cancer if disease-free for one year or more
  • Patients with malignant pleural effusions or significant pericardial effusions
  • Pregnant or lactating females
  • Severe neuropathy greater than or equal to grade 2
  • Severe sensorineural hearing loss greater or equal to grade 2
  • No clinically significant history of cardiac disease, (i.e. uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the past year, or cardiac ventricular arrhythmias requiring medication)
  • Any significant or severe medical conditions or psychiatric or social conditions that would preclude adherence to the protocol or compliance with study treatments
Both
Not Provided
No
United States
 
NCT01411098
7506, NCI-2011-01752, P30CA015704
No
University of Washington
University of Washington
National Cancer Institute (NCI)
Principal Investigator: Shilpen Patel Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
University of Washington
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP